Literature DB >> 18470574

Glucose levels and insulin secretion in surgery-induced hyperglycemia in normoglycemic obese patients.

Marina Michalaki1, Venetsana Kyriazopoulou, Panagiotis Mylonas, Maria-Ioanna Argentou, Yves Debaveye, Fotis Kalfarentzos, Apostolos G Vagenakis.   

Abstract

BACKGROUND: Transient hyperglycemia is commonly observed in non-diabetic subjects during surgery. We undertook this study to investigate (1) insulin secretion pattern and glucose levels during elective surgery, and (2) the role of pre-operative fasting in the development of surgery-induced hyperglycemia.
METHODS: We examined 21 severely obese normal glucose tolerant patients, who underwent bariatric surgery. From the 21 operated subjects, 14 remained fasted while seven patients received 75 g glucose the preoperative night. They sampled at baseline and from the onset of operation frequently for 9 h thereafter, for measuring serum insulin and glucose.
RESULTS: Hyperglycemia developed within 1 h from the onset of operation and lasted 9 h. The administration of 75 g glucose the preoperative night prevented surgery-induced hyperglycemia. Insulin profile analyzed by deconvolution analysis was similar between fasted patients and those who received 75 g glucose. Serum insulin was suppressed at the beginning of the surgery and reached baseline values 4 h thereafter.
CONCLUSION: Hyperglycemia occurred within 1 h from the beginning of surgery and sustained for at least 9 h while insulin levels are suppressed or unaltered compared to baseline values in euglycemia. The administration of 75 g glucose the preoperative night prevents surgery-induced hyperglycemia without altering the profile of insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18470574     DOI: 10.1007/s11695-008-9501-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  47 in total

1.  Approximate entropy as a measure of system complexity.

Authors:  S M Pincus
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

Review 2.  The dynamic neuroendocrine response to critical illness.

Authors:  Lies Langouche; Greet Van den Berghe
Journal:  Endocrinol Metab Clin North Am       Date:  2006-12       Impact factor: 4.741

Review 3.  Insulin resistance: a marker of surgical stress.

Authors:  A Thorell; J Nygren; O Ljungqvist
Journal:  Curr Opin Clin Nutr Metab Care       Date:  1999-01       Impact factor: 4.294

4.  In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts.

Authors:  N Pørksen; B Nyholm; J D Veldhuis; P C Butler; O Schmitz
Journal:  Am J Physiol       Date:  1997-11

5.  The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations.

Authors:  J D Veldhuis; M L Carlson; M L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Failure of insulin response to glucose load during operation and after myocardial infarction.

Authors:  S P Allison; K Prowse; M J Chamberlain
Journal:  Lancet       Date:  1967-03-04       Impact factor: 79.321

7.  Preoperative oral carbohydrate administration reduces postoperative insulin resistance.

Authors:  J Nygren; M Soop; A Thorell; S Efendic; K S Nair; O Ljungqvist
Journal:  Clin Nutr       Date:  1998-04       Impact factor: 7.324

8.  Plasma insulin and surgery. I. Early changes due to operation in the insulin response to glucose.

Authors:  A E Giddings; D Mangnall; B J Rowlands; R G Clark
Journal:  Ann Surg       Date:  1977-12       Impact factor: 12.969

9.  Preoperative oral carbohydrate treatment attenuates immediate postoperative insulin resistance.

Authors:  M Soop; J Nygren; P Myrenfors; A Thorell; O Ljungqvist
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-04       Impact factor: 4.310

Review 10.  Inflammatory status and insulin resistance.

Authors:  Robert F Grimble
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2002-09       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.